Central diabetes insipidus secondary to COVID-19 infection: a case report
Abstract Background Novel coronavirus disease 2019 (COVID-19) mainly affects the lungs, but can involve several other organs. The diagnosis of acute and chronic sequelae is one of the challenges of COVID-19. The current literature proposes that severe acute respiratory syndrome coronavirus 2 (SARS-C...
Autors principals: | Ali Yavari, Zahra Sharifan, Bagher Larijani, Ali Mosadegh Khah |
---|---|
Format: | Article |
Idioma: | English |
Publicat: |
BMC
2022-05-01
|
Col·lecció: | BMC Endocrine Disorders |
Matèries: | |
Accés en línia: | https://doi.org/10.1186/s12902-022-01048-w |
Ítems similars
-
Drugs for the treatment of central diabetes insipidus: historical background and modern opportunities
per: Dar'ya S. Mikhaylova, et al.
Publicat: (2017-03-01) -
Modern Approach in Treatment of Diabetes Insipidus
per: Elvedina Kapić, et al.
Publicat: (2005-05-01) -
Treatment with various forms of desmopressin in a patient with apparently non-idiopathic diabetes insipidus
per: Ekaterina A. Pigarova
Publicat: (2018-04-01) -
Selection of desmopressin preparations for the treatment of central diabetes insipidus
per: Elena V. Biryukova
Publicat: (2017-12-01) -
The study of clinical bioequivalence drug Nativa (generic desmopressin acetate tablets) in patients with central diabetes insipidus
per: Ekaterina A. Pigarova, et al.
Publicat: (2016-03-01)